Yumab GmbHAntibody-drug conjugates (ADCs) hinge on the antibody, not merely the payload or linker. Antibody precision defines efficacy, safety and therapeutic window. Emerging antibody formats – bispecifics, conditional designs and TCR-mimics – expand target space, demanding rigorous engineering to realise next-generation ADC potential.
Tag Archive for: ADC
Die Hoffotografen GmbHSolid tumours pose major obstacles for cell therapies, but German-American biotech T-knife is tackling them head-on. CEO Tom Soloway and CTO Elisa Kieback share how their “supercharged” TCR-Ts are engineered to overcome these challenges.
BIOCOM InterrelationsFollowing its US$361 m Series C financing, Tubulis AG presented first Phase I/IIa data on its lead ADC, TUB-040, at ESMO 2025 in Berlin. The study focuseds on patients with platinum-resistant ovarian cancer (PROC). TUB-040 shows clear differentiation potential
Adcytherix SASFrench ADC start-up Adcytherix SAS has added €105m Series A funding to a €30m seed financing round closed last year. With the money, the company will start a Phase I study with its lead ADCX-020 in Q1 2026 and develop novel payloads to break ADC therapy resistance.
Tubulis GmbHMunich-Martinsried-based biotech Tubulis has closed a €308 million (USD 361 million) Series C financing round – the largest of its kind for a still existing European biotechnology company at the Series C stage and also the world’s largest financing for a private ADC (antibody–drug conjugate) developer. The attractivity lays in the technologyplatform of linking the payload.
Synaffix/LanzaElevation Oncology Inc has inked a US$368m license agreement with Lonza subsidiary Synaffix BV under which Synaffix will link Elevation’s HER3 antibody seribantumab to a monomethyl auristatin E (MMAE) toxic payload with broad therapeutic index.
Alentis TherapeuticsSwiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours.
BIOCOMMonoclonal antibodies still dominate the US$417bn biologics market. After decades of development, however, improved antibodies and protein formats with better target selectivity and safety profiles are now hitting markets and pipelines. A range of bispecific antibodies and antibody-drug conjugates – along with CAR-Ts, TCR-RTs and NK cell-based immunoreceptor constructs – were in focus at the PEGS Europe Summit.
Antibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development.
Adcendo ApSDanish ADC maker Adcendo ApS has licenced the rights to commercialise Multitude Therapeutics Inc’s first-in-class ADCE-T02 globally except the Greater China region.
Tag Archive for: ADC
The 16th World ADC London takes place on 23–26 February 2026, bringing together over 800 senior decision-makers from biopharma, KOL oncologists, service providers, investors, and regulators. As Europe’s largest forum dedicated to antibody–drug conjugates (ADCs), the summit offers a comprehensive programme covering discovery, translational science, clinical development, manufacturing, and regulatory strategy.
ADCs continue to transform oncology, delivering potent therapies directly to cancer cells while minimising off-target toxicity. As the field moves towards earlier-line treatments, developers face complex challenges, from payload optimisation and resistance mechanisms to scalable manufacturing. World ADC London 2026 addresses these challenges head-on, providing actionable insights from 110 global speakers across five content streams over four days of in-depth sessions, workshops, and panel discussions.
This year’s programme highlights next-generation payloads, bispecific constructs, dual-payload strategies, and non-antibody conjugates, giving attendees practical guidance on overcoming resistance, improving safety, and navigating evolving regulatory expectations. Strategic and commercial considerations are also central, with presentations from leading clinicians, regulatory experts, and investors sharing insights into clinical advancement, partnership opportunities, and emerging trends shaping the ADC landscape.
Networking remains a cornerstone of the event, with 14 hours of dedicated interaction built into the agenda. Structured networking sessions, one-to-one meetings, and informal discussions enable delegates to forge collaborations, explore licensing and investment opportunities, and exchange knowledge with peers from across the global ADC community.
Whether you are an early-career scientist, an experienced developer, or a strategic investor, World ADC London 2026 is the must-attend event for staying at the forefront of ADC innovation. From cutting-edge science to strategic insights and invaluable industry connections, the summit empowers participants to advance the next generation of ADCs from the lab to clinical and commercial success.
Contact: info@hansonwade.com | Event Guide | Registration & Pricing